Dosing & Uses
Dosage Forms & Strengths
injection, suspension hemagglutinin H5N1 strain
- Only to government agencies and for stockpiles
H5N1 Influenza (Avian Flu)
Indicated for active immunization of adults aged 18-64 years at increased risk of exposure to H5N1
2-dose immunization series
90 mcg (1 mL) IM once; administer second 1 mL dose 28 days later (range 21-35 days)
Safety and efficacy not established for adults >64 years
Specific strain: A/Vietnam/1203/2004
Also contains thimerosal, chicken protein, porcine gel, and egg protein
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Local pain (74%)
Local tenderness (70%)
Local erythema/redness (20%)
Upper respiratory infection (2%)
Nasal congestion (1%)
Documented hypersensitivity to vaccine, egg proteins, or other vaccine components
Immune response may not be fully obtained in immunocompromised patients.
Use caution if Guillain-Barre syndrome has occurred within 6 weeks of prior influenza vaccine
Syncope accompanied by transient visual disturbances, tonic-clonic movements reported with injectable vaccines
Immunocompromised patients receiving chemo/radiation therapy or other immunosuppressive therapy may have reduced response to vaccine
Vaccine may not provide effective immunity in all patients
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Unknown if distributed in human breastmilk; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Influenza vaccines induce antibodies against the viral HA in the vaccine, which then blocks viral attachment to human respiratory cells
Te mechanism of action of type A (H5N1) influenza virus is not well understood; promotes active immunity to avian influenza
In clinical trials, a 4-fold increase in antibody titers was seen in up to 58% of patients 28 days after second dose
Administer preferably in lateral aspect of deltoid muscle of upper arm
Do not inject gluteal region or areas where a major nerve trunk might be present
Needles less than 1-inch may not penetrate the muscle tissue; use needles at least 1-inch in size
Refrigerate at 2-8 C (35-46 F)
Do not Freeze (discard if frozen)
Protect from light
Do not use after expiration date.
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.